During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Medtronic PLC (NYSE:MDT)

  • Dividend Yield: 3.22%
  • Mizuho analyst Anthony Petrone maintained an Outperform rating and cut the price target from $125 to $120 on April 13, 2026. This analyst has an accuracy rate of 63%
  • Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and lowered the price target from $108 to $106 on April 9, 2026. This analyst has an accuracy rate of 54%.
  • Recent News: Medtronic announced that it will report financial results on Wednesday, June 3, for its fourth quarter.
  • Benzinga Pro’s real-time newsfeed alerted to latest MDT news.

AbbVie (NYSE:ABBV)

  • Dividend Yield: 3.29%
  • Guggenheim analyst Vamil Divan maintained a Buy rating and increased the price target from $242 to $249 on April 10, 2026. This analyst has an accuracy rate of 79%.
  • Cantor Fitzgerald analyst Carter Gould maintained an Overweight rating and slashed the price target from $250 to $240 on April 8, 2026. This analyst has an accuracy rate of 64%
  • Recent News: AbbVie said it will announce its first-quarter 2026 financial results before the opening bell on Wednesday, April 29.
  • Benzinga Pro's real-time newsfeed alerted to latest ABBV news

Viatris Inc (NASDAQ:VTRS)

  • Dividend Yield: 3.45%
  • Barclays analyst Glen Santangelo maintained an Overweight rating and raised the price target from $15 to $17 on March 24, 2026. This analyst has an accuracy rate of 51%.
  • Piper Sandler analyst David Amsellem maintained a Neutral rating and increased the price target from $9 to $12 on Jan. 28, 2026. This analyst has an accuracy rate of 76%.
  • Recent News: Viatris announced it will report first-quarter financial results on Thursday, May 7.
  • Benzinga Pro’s real-time newsfeed alerted to latest VTRS news

Photo via Shutterstock